Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1959
  • Dowloads 150

Case Reports

Open Access

Uterine curettage prior to supracervical hysterectomy identifies a placental trophoblastic tumor – a case study

  • G. Raba1,2,*,
  • M. Wieliczko2
  • E. KRASNIANIN1

1University of Rzeszow, Rzeszow

2Provincial Hospital in Przemysl, Przemysl (Poland)

DOI: 10.31083/j.ejgo.2020.02.4927 Vol.41,Issue 2,April 2020 pp.296-298

Published: 15 April 2020

*Corresponding Author(s): G. Raba E-mail: XXX

PDF (3.38 MB) View Full-text

Abstract

Uterine fibroid surgical preparation should take into account the risk of an unexpected concurrent malignancy. Curettage prior to uterine fibroid surgery isn’t standard procedure, but incorporation of curettage may discover rare pathologies. This case study shows that routine curettage prior to uterine fibroid surgical treatment correlates with diagnosis of unexpected pathological findings -even a neoplastic transformation as rare as placental site trophoblastic tumor (PSTT).

Keywords

Placental site trophoblastic tumor; Uterine curetage; Pathology.

Cite and Share

G. Raba,M. Wieliczko,E. KRASNIANIN. Uterine curettage prior to supracervical hysterectomy identifies a placental trophoblastic tumor – a case study. European Journal of Gynaecological Oncology. 2020. 41(2);296-298.

URL:

https://www.ejgo.net/articles/10.31083/j.ejgo.2020.02.4927

References

[1] Yuk J.S., Shin J.Y., Moon H.S., Lee J.H.: “The incidence of unexpected uterine malignancy in women undergoing hysteroscopic myomectomy or polypectomy: A national population-based study”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2018, 224, 12.

[2] Multinu F., Casarin J., Hanson K.T., Angioni S., Mariani A., Habermann E.B., et al.: “Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation”. JAMA Surg., 2018, 53, 180141.

[3] Lan C., Li Y., He J., Liu J.: “Placental site trophoblastic tumor: lymphatic spread and possible target markers”. Gynecol. Oncol., 2010, 116, 430.

[4] McCarthy W.A., Paquette C., Colavita M., Lawrence W.D.: “Atypical placental site nodule arising in a postcesarean section scar: case report and review of the literature”. Int. J. Gynecol. Pathol., 2019, 38, 7.

[5] Baergen R.N., Rutgers J.L., Young R.H., Osann K., Scully R.E.: “Placental site trophoblastic tumor: a study of 55 cases and review of the literature emphasizing factors of prognostic significance”. Gynecol. Oncol., 2006, 100, 511.

[6] Schmid P., Nagai Y., Agarwal R., Hancock B., Savage P.M., Sebire N.J., Lindsay I., et al.: “Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study”. Lancet, 2009, 374, 48.

[7] Rhoton-Vlasak A., Wagner J.M., Rutgers J.L., Baergen R.N., Young R.H., Roche P.C., et al.: “Placental site trophoblastic tumor: human placental lactogen and pregnancy-associated major basic protein as immunohistologic markers”. Hum. Pathol., 1998, 29, 280.

[8] Veras E., Kurman R.J., Wang T.L., Shih I.M.: “PD-L1 expression in human placentas and gestational trophoblastic diseases”. Int. J. Gynecol. Pathol., 2017, 36, 146.

[9] Bouquet de la Jolinière J., Khomsi F., Fadhlaoui A., Ben Ali N., Dubuisson J.B., Feki A.: “Placental site trophoblastic tumor: a Case Report and Review of the Literature”. Front. Surg., 2014, 1, 31.

[10] Schild R., Kutta T.: “Status of fractionated abrasion and vaginal endocervical cytology in diagnosis of endometrial cancer”. Geburtshilfe Frauenheilkd., 1992, 52, 467.

[11] Bang T.F., Schei B., Halgunset J.: “Examination of uterine hemorrhagic disorders using fractionated abrasion”. Tidsskr. Nor. Laegeforen., 1991, 111, 2407.
[12] Raba G., Baran P.: “Hemodynamic parameters following bilateral internal iliac arteries ligation as a treatment of intrapartum hemorrhage”. Ginekol. Pol., 2009, 80, 179.

Submission Turnaround Time

Top